Straits Times Index
3,265.95 +1.42 (+0.04%) S&P 500
5,198.11 +10.44 (+0.20%) Dow
39,215.22 +158.83 (+0.41%) Nasdaq
16,314.23 +11.48 (+0.07%) Bitcoin USD
62,071.16 -148.91 (-0.24%) CMC Crypto 200
1,337.61 +37.51 (+2.89%)
Tarsus Pharmaceuticals, Inc. (TARS)
- GuruFocus.com
Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
Explore key financial outcomes and strategic insights from Tarsus Pharmaceuticals' first quarter of 2024, highlighting significant sales growth and market penetration efforts.
- Zacks
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 12.17% and 53.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and remain on-track for broad commercial coverage by the end of 2024 and Medicare coverage beginning in 2025 Expanded sales force on-track to be in the field by the end of the third quarter 2024 Strengthened financial position with an approximately $108 million public equity offering and $200 million fi
